Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History BIIB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics BIIB

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Biogen Inc

BIIB
Current price
128.69 USD +0.51 USD (+0.40%)
Last closed 127.50 USD
ISIN US09062X1037
Sector Healthcare
Industry Drug Manufacturers - General
Exchange NASDAQ
Capitalization 19 829 635 072 USD
Yield for 12 month -42.87 %
1Y
3Y
5Y
10Y
15Y
BIIB
21.11.2021 - 28.11.2021

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS; and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA. It offers RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, and biosimilars. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; and Sage Therapeutics, Inc., as well as collaborations with Fujirebio to identify and develop biomarkers for tau pathology in the brain and Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts. Address: 225 Binney Street, Cambridge, MA, United States, 02142

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

172.20 USD

P/E Ratio

13.37

Dividend Yield

Financials BIIB

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures BIIB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+9 675 900 000 USD

Last Year

+9 835 600 000 USD

Current Quarter

+2 431 000 000 USD

Last Quarter

+2 454 700 000 USD

Current Year

+7 365 500 000 USD

Last Year

+7 302 200 000 USD

Current Quarter

+1 801 700 000 USD

Last Quarter

+1 871 200 000 USD
EBITDA 3 080 900 096 USD
Operating Margin TTM 28.05 %
Price to Earnings 13.37
Return On Assets TTM 5.43 %
PEG Ratio 6.24
Return On Equity TTM 9.19 %
Wall Street Target Price 172.20 USD
Revenue TTM 9 816 399 872 USD
Book Value 115.90 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 6.10 %
Dividend Yield
Gross Profit TTM 7 426 200 064 USD
Earnings per share 10.12 USD
Diluted Eps TTM 10.12 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY -39.30 %
Profit Margin 15.07 %

Stock Valuation BIIB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 13.37
Forward PE 8.90
Enterprise Value Revenue 2.40
Price Sales TTM 2.02
Enterprise Value EBITDA 8.70
Price Book MRQ 1.15

Technical Indicators BIIB

For 52 Weeks

110.04 USD 236.48 USD
50 Day MA 127.48 USD
Shares Short Prior Month 3 389 242
200 Day MA 146.94 USD
Short Ratio 2.14
Shares Short 4 000 596
Short Percent 2.99 %